Search the Newsreel

Colgate-Palmolive (CL) Earnings Keep Fair Value In Focus

Moleculin Biotech prices offering with warrants for 37,130,001 shares at $0.75 exercise price

Moleculin Biotech has priced a $9.3 million public offering that includes warrants to purchase up to 37,130,001 shares at an exercise price of $0.75 per share. The offering, which includes 12,376,667 common shares or pre-funded warrants, is expected to close around August 3, 2026. …

Molecular Partners AG (0QXX) Q4 2023 Earnings Report - Results, Call & Slides

Molecular Partners AG (0QXX) announced its Q4 2023 earnings, beating EPS and revenue expectations. The company reported an actual EPS of -CHF0.60 against a consensus of -CHF0.97, and actual revenue of CHF1.03M significantly surpassed the expected CHF400.00K. The next earnings report for Q2 2026 …

Moleculin Biotech updates Annamycin data, prices stock offering at $0.75

Moleculin Biotech has released updated preliminary blinded data from Part A of its MIRACLE trial for Annamycin, signaling stability in results despite the data remaining unblinded. Concurrently, the company priced a public offering at $0.75 per share, indicating confidence in the clinical trajectory to …

Molson Coors Beverage Company Revenue Breakdown – NYSE:TAP

Molson Coors Q2 Earnings Approaching: Will It Surprise Investors?

Molson Coors Beverage Company TAP is expected to register declines in its top and bottom lines when it reports second-quarter 2026 earnings on Aug. 6, before market open. The Zacks Consensus Estimate for revenues is pegged at $3.1 billion, indicating a 3.2% decline from …

Molecular Partners AG (MOLN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Molecular Partners AG (MOLN), focusing on its current valuation score, P/E ratio, and ranking within the Biotechnology & Medical Research industry. As of July 31, 2026, the company's valuation score is 7.34, ranking 184 out of 385, …

What Colgate-Palmolive (CL)'s Q2 2026 Margin Squeeze And Steady Guidance Mean For Shareholders

Colgate-Palmolive reported increased sales in Q2 2026 but experienced a dip in net income and earnings per share due to margin squeeze from rising costs. Despite this, the company maintained its full-year 2026 guidance for 2% to 6% net sales growth and double-digit GAAP …

Colgate-Palmolive Co reports results for the quarter ended June 30 - Earnings Summary

Colgate-Palmolive Co (CL) has released its earnings summary for the quarter that concluded on June 30. The report, sourced from Refinitiv, is available for full viewing to subscribers of TradingView's news services.

Molecular Partners AG (MOLN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Molecular Partners AG (MOLN), highlighting its volatility, financial risk, and investment risk. The company

Moleculin Biotech (Nasdaq:MBRX) - Stock Analysis

Moleculin Biotech (MBRX) is a late-stage pharmaceutical company developing therapies for tumors and viruses, with its lead drug Annamycin undergoing Phase 2/3 trials for relapsed or refractory acute myeloid leukemia (R/R AML) and soft tissue sarcoma lung metastases. The company faces significant financial risks, …

Moleculin Biotech prices $9.3 million public offering

Moleculin Biotech (NASDAQ:MBRX) has priced a public offering of 12,376,667 shares of common stock and warrants for an additional 37,130,001 shares at $0.75 per share and warrant, totaling $9.3 million. The company plans to use the net proceeds to advance its lead drug candidate, …

Moleculin Announces Pricing of $9.3 Million Public Offering

Moleculin Biotech, Inc. announced the pricing of a $9.3 million public offering, selling 12,376,667 shares of common stock (or pre-funded warrants) and warrants to purchase up to 37,130,001 shares at $0.75 per unit. The offering is expected to close around August 3, 2026, with …

B. Riley Initiates 4D Molecular Therapeutics at Buy With $37 Price Target

B. Riley has initiated coverage on 4D Molecular Therapeutics (FDMT) with a "Buy" rating and a price target of $37. The company, a late-stage biotechnology firm, is advancing several therapeutic candidates, including 4D-150 for wet age-related macular degeneration and diabetic macular edema, and 4D-710 …

Colgate-Palmolive hält an Gewinnprognose für das Gesamtjahr 2026 fest

Colgate-Palmolive reaffirms annual sales forecast on weak North America demand

Colgate-Palmolive affirmed its annual

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Moleculin Biotech announced positive interim blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in combination with cytarabine (AnnAraC) for relapsed or refractory AML. The trial showed a 37% composite complete remission (CRc) rate, with essentially identical rates for …

12 Health Care Stocks Moving In Friday's Pre-Market Session

This article identifies 12 healthcare stocks experiencing significant movement in pre-market trading on Friday. It lists several gainers, including Replimune Group and Moleculin Biotech, which saw substantial increases, and notable decliners such as Karyopharm Therapeutics and Bioage Labs. The movements are attributed to various …

Colgate-Palmolive (CL) Q2 2026 Earnings

Colgate-Palmolive (CL) reported strong Q2 2026 earnings, beating EPS estimates by 4.5% with $0.99, extending its beat streak to five quarters. The company's revenue of $5.36 billion met expectations, and it saw accelerating volume growth despite a sales decline in North America. Following these …

Insight Molecular Diagnostics Inc. Revenue Breakdown – NASDAQ:IMDX

Insight Molecular Diagnostics Inc. (IMDX) generated $4.05 million USD last year, primarily from its Diagnostic Tests segment. The United States was the largest contributor to this revenue, accounting for $4.03 million USD. This represents a significant increase from the previous year's figures of $1.88 …

Colgate-Palmolive (CL) Q2 Earnings and Revenues Top Estimates

Colgate-Palmolive (CL) reported strong Q2 earnings, beating Zacks Consensus Estimates with $0.99 per share and revenues of $5.36 billion. The company has consistently surpassed EPS estimates over the last four quarters and seen its shares gain 15.9% year-to-date, outperforming the S&P 500. While its …

Colgate-Palmolive Sales Rise Despite Choppy Backdrop

Colgate-Palmolive reported increased sales in the second quarter, despite a challenging consumer market. The company's revenue grew by 4.9% to $5.36 billion. However, its profit declined to $693 million, or 86 cents per share, from $743 million, or 91 cents per share, in the …

Colgate-Palmolive tops EPS estimates, but shares dip

Colgate-Palmolive (NYSE:CL) reported second-quarter earnings that surpassed analyst expectations, with adjusted EPS of $0.99 against an estimate of $0.95. Revenue matched consensus at $5.36 billion, marking a 4.9% increase year-over-year. Despite these positive results and an increase in advertising spend, the company's shares experienced …

Colgate-Palmolive supera las estimativas de BPA, pero sus acciones caen

Colgate-Palmolive (NYSE:CL) Posts Q2 CY2026 Sales In Line With Estimates

Colgate-Palmolive (NYSE:CL) reported Q2 CY2026 results, with sales growing 4.9% year-on-year to $5.36 billion, meeting Wall Street estimates. The company's non-GAAP profit per share of $0.99 exceeded analyst expectations by 4.5%. Despite strong financial performance and organic revenue growth in several divisions, the company's …

Colgate-Palmolive superaron 0.04$ las previsiones de BPA en el segundo trimestre del año

Colgate-Palmolive supera por 0,04$ las previsiones de BPA en el segundo trimestre del año

Colgate keeps 2026 sales outlook, lifts non-GAAP EPS growth

Colgate-Palmolive (NYSE: CL) announced its second-quarter 2026 results, showing a 4.9% increase in net sales and a 2.4% organic sales growth, despite a 5% GAAP EPS decrease. The company maintained its full-year 2026 net sales and GAAP EPS guidance but upgraded its non-GAAP (Base …

Colgate-Palmolive (CL) Tops Q2 EPS by 4c; Offers Guidance

Colgate-Palmolive (CL) reported strong Q2 earnings, surpassing analyst estimates by $0.04 with an EPS of $0.99 and meeting revenue expectations at $5.36 billion. The company also provided its full-year 2026 guidance, expecting net sales to be up 2% to 6% and organic sales growth …

Shandong Molong Raises Registered Capital After H-Share Placement

Colgate-Palmolive Company $CL Shares Sold by South Dakota Investment Council

The South Dakota Investment Council reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 29.2% in the first quarter, selling over 31,000 shares but retaining 76,661 shares valued at $6.5 million. Despite this institutional selling, analysts generally maintain a "Moderate Buy" rating with an average …

Groupe la Francaise Boosts Stock Holdings in Colgate-Palmolive Company $CL

Groupe la Francaise significantly increased its stake in Colgate-Palmolive Company (NYSE:CL) by 295.3% in the first quarter, now owning 138,723 shares valued at $11.666 million. Other institutional investors like Norges Bank and Bank of New York Mellon Corp also adjusted their holdings. The article …

Colgate-Palmolive Company $CL Shares Sold by Empowered Funds LLC

Empowered Funds LLC reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 21.2% in the first quarter, selling 35,005 shares and bringing its total holdings to 130,068 shares valued at $11.086 million. Despite this, other institutional investors like Quantinno Capital Management LP and Lazard Asset …

B.Riley initiates 4D Molecular Therapeutics stock coverage with buy rating

B.Riley has initiated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy rating and a price target of $37.00, suggesting substantial upside from its current price and indicating it may be undervalued. The firm views the company's lead candidate, 4D-150, for neovascular AMD as …

Colgate-Palmolive Lifts FY26 Adj. Earnings View, Despite Weak Q2 Profit; Stock Down

Colgate-Palmolive reported a weak Q2 profit despite higher net sales but confirmed its fiscal 2026 outlook for earnings and sales growth, while lifting guidance for Base Business earnings per share and gross profit margin. The company's shares were down approximately 2.78% in pre-market trading. …

Colgate-Palmolive falls after reporting soft organic sales in North America (CL:NYSE)

Colgate-Palmolive (CL) shares declined after its Q2 earnings report revealed a 4.9% revenue increase to $5.36 billion. However, organic sales growth was a softer 2.4%, impacted negatively by lower private label pet food sales. The report indicated some softness in North American organic sales.